Worldwide Antibody Drug Conjugates Industry to 2026 - Growing Geriatric Population is Driving Growth -

·4 min read

DUBLIN, January 21, 2022--(BUSINESS WIRE)--The "Antibody Drug Conjugates Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to's offering.

The antibody drug conjugates market is projected to register a CAGR of 12.8% during the forecast period.

Companies Mentioned

  • Seagen Inc.

  • ImmunoGen Inc.

  • Mersana Therapeutics

  • Pfizer Inc.

  • F Hoffmann-La Roche Ltd

  • Sorrento Therapeutics Inc.

  • Oxford BioTherapeutics

  • AbbVie Inc.

  • Takeda Pharmaceutical Company Ltd

  • AstraZeneca

  • ADC Therapeutics SA

  • Sterling Pharma Solutions Limited

  • Catalent Inc.

  • Antikor

Key Market Trends

The Breast Cancer Segment is Expected to Account for the Largest Market Share During the Forecast Period

According to an article published in 2020 by OncLive, in 2019, approximately 15.2% of cases in the United States were found to be breast cancer incidence of all types of a new cancer diagnosis. According to Globocan Data 2020, cancer incidence is expected to increase from 19.3 million in 2020 to 30.2 million people in 2040 worldwide, whereas breast cancer incidences are expected to grow from 2.26 million people in 2020 to 3.19 million in 2040.

Initially, HER2-positive breast cancer was associated with a high rate of reoccurrence and less rate of survival. According to an article published in 2020 by Genetherapy Genetic Medicine, of all the incidences of breast cancer, HER2-positive breast cancer accounts for almost 15%. This article also says that the estimated 5-year survival rates are 83% for hormone receptor-negative, HER2-positive breast cancer and 89% for hormone receptor-positive, HER2-positive breast cancer.

With the availability of trastuzumab and other specific HER2 antigen-targeted therapies, there have been improved outcomes for this type of cancer treatment. Additionally, in March 2021, Pyxis Oncology and Pfizer entered an agreement for the development and commercialization of two ADC candidates, PYX-201 and PYX-203for, to improve the survival rate.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is the most COVID-influenced area across the world. Because of the flare-up of COVID-19, the market is expected to face slight difficulty in attributing to the postponement in diagnosis, drug deficiencies, and others. The antibody drug conjugate market in North America is exceptionally competitive due to the presence of an enormous level of market players.

North America is expected to control the worldwide market rapidly because of the expanding multiplication of technologically innovative technologies in the countries of the region such as the United States, Canada, and Mexico. North America is a very developed region as far as clinical information, and the utilization of ADCs is considered and makes up the vast majority of the established market. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals Inc. to develop antibody drug conjugates and several other therapies for cancer. Moreover, Asia Pacific is expected to contribute significantly to the market growth during the forecast time because of the COVID-19 flare in Wuhan Province in China and further adjoining nations.

According to the American Cancer Society, in 2020, in the United States, an estimated 276,480 new cases of invasive breast cancer have been diagnosed among women. Likewise, 48,530 instances of in situ breast cancer have been analyzed among ladies, and the quantity of malignant breast cases is expected to grow during the forecast period. Additionally, North America is found to hold a significant share of the antibody drug conjugates market, and it is relied upon to show a similar pattern over the forecast time frame, without huge variances. The rising prevalence of breast cancer and the presence of better healthcare infrastructure in the region are expected to drive the overall growth of the market over the forecast period.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Incidence of Cancer

4.2.2 Growing Geriatric Population

4.2.3 Increasing Research and Development Activities for the Development of Novel Therapeutics

4.3 Market Restraints

4.3.1 Stringent Government Regulations

4.3.2 High manufacturing Costs of Antibody Drug Conjugates

4.4 Industry Attractiveness - Porter's Five Forces Analysis


5.1 By Product Type

5.2 By Application

5.3 By Technology

5.4 By Target Type

5.5 By End Users

5.6 By Geography


6.1 Company Profiles


For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting